![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, December 03, 2021 10:37:21 AM
being peer review published in the Lancet is a major milestone! hugely legitimizing and will pave the way to approvals and major revenue for $HGEN - the market is completely oblivious to the opportunity here at the moment
It is frustrating that the market doesn't respect the peer review news but ultimately it is regulatory agencies that matter. The US FDA and MHRA will respect lenzilumab getting peer reviewed in The Lancet. Government regulatory agencies also understand the importance of lenz being variant agnostic. The currently available armamentarium is ill-equipped to fight the Omicron variant. Lenz has 154% efficacy and will fight Omicron equally well as previous variants. Lenzilumab's time is coming.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM